CACNA1G Gene
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CACNA1G Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CACNA1G</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Calcium Voltage-Gated Channel Subunit Alpha1 G</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q22</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8912</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000006283</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>O43497</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Association Type</td>
</tr>
<tr>
<td class="label">Childhood Absence Epilepsy</td>
<td>Causative</td>
</tr>
<tr>
<td class="label">Spinocerebellar Ataxia</td>
<td>Causative</td>
</tr>
<tr>
<td class="label">[Parkinson's Disease](/diseases/parkinsons-disease)</td>
<td>Risk Modulator</td>
</tr>
<tr>
<td class="label">[Alzheimer's Disease](/diseases/alzheimers-disease)</td>
<td>Risk Modulator</td>
</tr>
<tr>
<td class="label">Bipolar Disorder</td>
<td>Risk Modifier</td>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Ethosuximide</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Valproic acid</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Zonisamide</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Pentobarbital</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/sca42nd" style="color:#ef9a9a">SCA42ND</a>, <a href="/wiki/absence-seizures" style="color:#ef9a9a">absence seizures</a>, <a href="/wiki/intellectual-disability" style="color:#ef9a9a">intellectual disability</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">neurodegeneration</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-8d270062" style="color:#ce93d8" title="Score: 0.48">Sleep Spindle-Synaptic Plasticity Enhanc...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>
Cacna1G Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Cacna1G Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@huguenard2002]
Gene Overview
CACNA1G (Calcium Voltage-Gated Channel Subunit Alpha1 G) encodes the α1G subunit of voltage-gated calcium channels, forming the pore of the T-type (CaV3.1) calcium channel. [@coutelier2015]
Function
The CACNA1G gene encodes the α1G subunit that forms the pore of the T-type (low-voltage activated) calcium channel (CaV3.1). T-type channels are characterized by:
- Low-voltage activation: Activates at relatively hyperpolarized membrane potentials (~-70 mV)
- Window current: Exhibits a small window current near resting membrane potential
- Rapid deactivation: Quick closing kinetics
- Thalamic expression: High expression in thalamic relay [neurons](/entities/neurons)
- Dendritic/somatic localization: Found on dendrites and cell bodies
T-type channels play critical roles in:
- Thalamic burst firing and sleep spindles
- Neuronal rhythmogenesis
- Low-threshold calcium spikes
- Pacemaker activity in certain neurons
- Regulation of neuronal excitability
Disease Associations
Key Mutations
- G436R: Gain-of-function causing absence epilepsy
- V1409I: Variant associated with increased epilepsy risk
- A1024E: Mutation causing SCA42 with cerebellar atrophy
Expression Pattern
CACNA1G shows region-specific expression:
- Thalamus: Highest expression in relay neurons (ventrobasal nucleus, intralaminar nuclei)
- Cerebellum: Purkinje cells and deep cerebellar nuclei
- [Cortex](/brain-regions/cortex): Layer 5 pyramidal neurons
- [Hippocampus](/brain-regions/hippocampus): CA1 pyramidal cells
- Substantia Nigra: Dopaminergic neurons
Therapeutic Targeting
T-type calcium channels are established drug targets:
Clinical Implications
- Epilepsy: T-type channel blockers are first-line for absence seizures
- Sleep disorders: Modulating thalamic T-type channels affects sleep architecture
- Neuroprotection: T-type blockers may protect against excitotoxicity
Key Publications
CACNA1G mutations in epilepsy - Chen Y, et al. Ann Neurol 2013 PMID: 23780923(https://pubmed.ncbi.nlm.nih.gov/23780923/)
T-type channels in thalamic oscillations - Huguenard JR, et al. Annu Rev Physiol 2002 PMID: 11830674(https://pubmed.ncbi.nlm.nih.gov/11830674/)
SCA42 caused by CACNA1G - Coutelier M, et al. Brain 2015 PMID: 26637561(https://pubmed.ncbi.nlm.nih.gov/26637561/)
T-type channels in Parkinson's - Surmeier DJ, et al. Trends Neurosci 2017 PMID: 28619450(https://pubmed.ncbi.nlm.nih.gov/28619450/)See Also
- [Voltage-Gated Calcium Channels](/mechanisms/ion-channel-dysfunction-neurodegeneration))
- [Calcium Signaling in Neurodegeneration](/mechanisms/calcium-dysregulation)
- [T-Type Calcium Channel](/proteins/cav3-1-protein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Epilepsy](/diseases/epilepsy)
- [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia)
External Links
- [NCBI Gene: CACNA1G](https://www.ncbi.nlm.nih.gov/gene/8912)
- [UniProt: CACNA1G](https://www.uniprot.org/uniprot/O43497)
- [Allen Brain Atlas: CACNA1G](https://human.brain-map.org/microarray/search/show?search_term=CACNA1G)
Overview
Cacna1G Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Cacna1G Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Chen Y, et al, Ann Neurol 2013;74:423-431 (2013)](https://pubmed.ncbi.nlm.nih.gov/23780923/)
[Huguenard JR, et al, Annu Rev Physiol 2002;64:159-187 (2002)](https://pubmed.ncbi.nlm.nih.gov/11830674/)
[Coutelier M, et al, Brain 2015;138:3163-3177 (2015)](https://pubmed.ncbi.nlm.nih.gov/26637561/)
[Surmeier DJ, et al, Trends Neurosci 2017;40:153-163 (2017)](https://pubmed.ncbi.nlm.nih.gov/28619450/)
[Hwang J, et al, Brain 2019;142:2086-2101 (2019)](https://pubmed.ncbi.nlm.nih.gov/31219789/)
[Cain SM, et al, Channels 2017;11:305-323 (2017)](https://pubmed.ncbi.nlm.nih.gov/28473962/)
[Cheong E, et al, J Neurosci 2014;34:12828-12840 (2014)](https://pubmed.ncbi.nlm.nih.gov/25232119/)
[Powell KL, et al, Brain 2014;137:2130-2140 (2014)](https://pubmed.ncbi.nlm.nih.gov/24736303/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Sleep Spindle-Synaptic Plasticity Enhancement](/hypothesis/h-8d270062) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CACNA1G
Pathway Context
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving CACNA1G Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)